Rowe J L, Brouhard B H, Dunn J K, Lagrone L
J Lab Clin Med. 1985 Jun;105(6):731-6.
Urinary N-acetyl-beta-D-glucosaminidase (NAG), a lysosomal hydrolase located the proximal tubule of the kidney, has been used as a marker for subtle renal injury. In humans and other animals with diabetes mellitus, urinary NAG activity has been shown to increase within 12 hours of the onset of hyperglycemia and glycosuria. Whether the rise in urinary NAG activity is in response to the hyperglycemia or to the osmotic diuresis associated with glycosuria is not known, nor has the time course of the rise in enzyme activity been determined. A study was designed using four groups of dogs to examine these possibilities: group 1 (n = 5), control dogs; group 2 (n = 5), mannitol-infused dogs; group 3 (n = 5), low-glucose dogs; and group 4 (n = 5), high-glucose dogs. In groups 2 and 4, mannitol and glucose, respectively, were infused at a rate to double urine flow from the left ureter without altering the contralateral urine volume. In group 3, sufficient glucose was infused to elevate left renal vein glucose level without producing glycosuria. In the control dogs infused with normal saline solution at a constant rate throughout the control and study periods, no differences were found in urinary NAG excretion when data from individual clearance periods were compared for the right and left kidneys. In the low-glucose dogs, urinary NAG/creatinine ratios were significantly increased (P less than 0.01) when the left and right kidneys were compared for the duration of the infusion.(ABSTRACT TRUNCATED AT 250 WORDS)
尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)是一种位于肾近端小管的溶酶体水解酶,已被用作轻微肾损伤的标志物。在人类和其他患有糖尿病的动物中,已显示在高血糖症和糖尿症发作后的12小时内,尿NAG活性会增加。尚不清楚尿NAG活性的升高是对高血糖的反应还是对与糖尿相关的渗透性利尿的反应,也未确定酶活性升高的时间进程。设计了一项研究,使用四组狗来检验这些可能性:第1组(n = 5),对照狗;第2组(n = 5),输注甘露醇的狗;第3组(n = 5),低血糖狗;第4组(n = 5),高血糖狗。在第2组和第4组中,分别以使左输尿管尿流加倍的速率输注甘露醇和葡萄糖,而不改变对侧尿量。在第3组中,输注足够的葡萄糖以提高左肾静脉葡萄糖水平而不产生糖尿。在整个对照期和研究期以恒定速率输注生理盐水的对照狗中,当比较左右肾各个清除期的数据时,尿NAG排泄未发现差异。在低血糖狗中,在输注期间比较左右肾时,尿NAG/肌酐比值显著升高(P小于0.01)。(摘要截短于250字)